Benefits, challenges and obstacles of adaptive clinical trial designs
Open Access
- 1 January 2011
- journal article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 6 (1), 79
- https://doi.org/10.1186/1750-1172-6-79
Abstract
In recent years, the use of adaptive design methods in pharmaceutical/clinical research and development has become popular due to its flexibility and efficiency for identifying potential signals of clinical benefit of the test treatment under investigation. The flexibility and efficiency, however, increase the risk of operational biases with resulting decrease in the accuracy and reliability for assessing the treatment effect of the test treatment under investigation. In its recent draft guidance, the United States Food and Drug Administration (FDA) expresses regulatory concern of controlling the overall type I error rate at a pre-specified level of significance for a clinical trial utilizing adaptive design. The FDA classifies adaptive designs into categories of well-understood and less well-understood designs. For those less well-understood adaptive designs such as adaptive dose finding designs and two-stage phase I/II (or phase II/III) seamless adaptive designs, statistical methods are not well established and hence should be used with caution. In practice, misuse of adaptive design methods in clinical trials is a concern to both clinical scientists and regulatory agencies. It is suggested that the escalating momentum for the use of adaptive design methods in clinical trials be slowed in order to allow time for development of appropriate statistical methodologies.Keywords
This publication has 7 references indexed in Scilit:
- Viewpoints on the FDA Draft Adaptive Designs Guidance from the PhRMA Working GroupJournal of Biopharmaceutical Statistics, 2010
- Adaptive design methods in clinical trials – a reviewOrphanet Journal of Rare Diseases, 2008
- Adaptive design method based on sum of p‐valuesStatistics in Medicine, 2006
- A Brief Review on Software Developments for Group Sequential and Adaptive DesignsBiometrical Journal, 2006
- Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working GroupJournal of Biopharmaceutical Statistics, 2006
- Statistical Consideration of Adaptive Methods in Clinical DevelopmentJournal of Biopharmaceutical Statistics, 2005
- A Multiple Testing Procedure for Clinical TrialsBiometrics, 1979